Downgrade Warning

Construction workers work at a site as the sun sets in the northern Indian city of Chandigarh December 16, 2006. REUTERS/Ajay Verma/Files

S&P affirms negative outlook on India, says chances of downgrade remain

Ratings agency Standard & Poor's affirmed India's sovereign rating at "BBB-minus" with a "negative" outlook, reiterating there was a one-in-three chance of a ratings downgrade over the next 12 months, a statement said on Friday.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Hefty Fine

Hefty Fine

Tribunal orders fined cement firms to pay $109 million fee.  Full Article 

Revitalising China

Revitalising China

China president takes charge of sweeping economic reform plans - sources.  Full Article 

Biggest Investors

Biggest Investors

China, India to be world's two biggest investors by 2030: World Bank.  Full Article 

ITC Results

ITC Results

ITC quarterly profit rises 19.5 pct, meets estimates.  Full Article 

Stretched Supplies

Stretched Supplies

A stretched Samsung chases rival Apple's suppliers.  Full Article 

Gold Market

Gold Market

Column - China, India demand not enough to save gold: Clyde Russell.  Full Article 

Chit Fund Scam

Chit Fund Scam

Fund scams target Indians beyond the reach of banks.  Full Article 

Foreign Inflows

Foreign Inflows

Foreign investors buy most Indian stocks in 3 months.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

MARKET EYE-Credit Suisse upgrades Dr Reddy's on US outlook

Related Topics

Stocks

   

Picture Gallery

India at Cannes

India at Cannes

Snapshots of Indian presence at the 66th Cannes Film Festival  Slideshow 

» Click here for more slideshows

Thu Dec 13, 2012 9:15am IST 

* Credit Suisse upgrades Dr. Reddy's Laboratories to
'outperform' from 'neutral' and raises its target price to 2,150
rupees from 1,900 rupees, citing expectations for a strong pick
up in U.S. sales in the coming quarters.
* Credit Suisse also notes the market share for Dr. Reddy's
Metoprolol drug, used for hypertension, is increasing.
* Dr. Reddy's also expects upcoming approval of two limited
competition products in the United States, Credit Suisse says
after meeting with the drug maker's management.
* Dr. Reddy's also expects fiscal 2015 growth in the United
States to be stronger than fiscal 2014 due to some "significant"
launches.

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
India Markets
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.